Chronic pancreatitis is a progressive inflammatory condition characterised by persistent pain, exocrine and endocrine dysfunction, and an elevated risk of pancreatic cancer. No therapy is approved to slow the underlying inflammation, so management is largely limited to pain control, enzyme replacement, and endoscopic or surgical intervention.

Drug developers are pursuing anti-inflammatory and anti-fibrotic approaches in this indication, and several programs have entered clinical development in recent years. Engagement from patient-advocacy organisations has grown alongside that activity, reflecting demand for a disease-modifying oral treatment.

Cibus Therapeutics develops orally administered small molecules, a route of administration that remains uncommon among programs targeting pancreatic inflammation, where existing care is largely supportive, procedural, or directed at symptom relief.

Its lead candidate is designed to act on several inflammatory signalling pathways simultaneously rather than on a single target. The company also draws on human-relevant stem-cell and organoid assays originating from Greenstone Biosciences to select and de-risk candidates before clinical testing.